The study, which sequenced and characterized 20 individual genomes, is part of a larger effort at Duke that aims to sequence around 200 genomes and 500 exomes from various disease cohorts including schizophrenia, epilepsy, ALS, and HIV.
At AACC, Rheonix presented three research studies demonstrating its integrated sample prep and PCR testing platform. In addition, the company reiterated its intent to seek regulatory clearance in the US for a warfarin sensitivity genotyping test by the end of the year; followed by a regulatory submission in China for an HPV test.
The study supports the idea of more widespread nucleic acid-based HIV diagnostic testing, which could be a boon for Gen-Probe and Novartis Diagnostics, which offer the only approved NAT for qualitative HIV diagnosis in the US.
The company will use the cash to continue developing in vitro diagnostic assays for its "chemistry and reagent device," or CARD — which integrates sample preparation, nucleic acid amplification, and endpoint detection all on a single microfluidics-based, point-of-care polymeric module.
Marine Biochem's enzymes are being used in diagnostic kits sold by Siemens and sample-prep kits being tested by another unnamed company — relationships Marine Biochem hopes will help spark its transition from a B2B vendor to a company that sells research tools directly to end users.
Although the collaboration is aimed at increasing physician knowledge of genomic testing associated with all HIV drugs, it appears to have stemmed from lower-than-expected sales of Pfizer's CCR5-antagonist Selzentry.